<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Levels of proinflammatory cytokines associate with risk for developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but whether <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> contributes to the development of <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e>, such as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>In the 1990s, we recruited 410 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> for studies of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and recorded their characteristics at enrollment </plain></SENT>
<SENT sid="2" pm="."><plain>During 12 years of follow-up, 59 patients developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> (17 per 1000 patient-years) and 84 patients died without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> (24 per 1000 patient-years) </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma markers of systemic <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, and the TNF pathway were measured in the study entry samples </plain></SENT>
<SENT sid="4" pm="."><plain>Of the examined markers, only TNF receptors 1 and 2 (TNFR1 and TNFR2) associated with risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>These two markers were highly correlated, but <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> associated more strongly with TNFR1 </plain></SENT>
<SENT sid="6" pm="."><plain>The cumulative incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> for patients in the highest TNFR1 quartile was 54% after 12 years but only 3% for the other quartiles (P&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>In Cox proportional hazard analyses, TNFR1 predicted risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> even after adjustment for clinical covariates such as urinary albumin excretion </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma concentration of TNFR1 outperformed <z:hpo ids='HP_0000001'>all</z:hpo> tested clinical variables with regard to predicting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Concentrations of TNFRs moderately associated with <z:hpo ids='HP_0011420'>death</z:hpo> unrelated to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, elevated concentrations of circulating TNFRs in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> at baseline are very strong predictors of the subsequent progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> in subjects with and without <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
</text></document>